---
title: "Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290885115.md"
description: "Moderna's 12-month average price target was raised to $47.45 by 27 analysts, up from $47.05. Based on the June 24 closing price, this implies a 21% downside potential. The consensus rating remains 'Hold', comprising 4 Buys, 18 Holds, and 5 Sells."
datetime: "2026-06-25T22:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290885115.md)
  - [en](https://longbridge.com/en/news/290885115.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290885115.md)
---

# Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside

-   According to estimates from 20 analysts, Moderna, Inc. stock's average price target has risen from $47.05 to $47.45, with forecasts ranging from $22 to $135 per share
-   Based on the Jun. 24 closing price, the updated target implies approximately 21% potential downside
-   Consensus rating remains at “Hold” across 27 covering analysts, with 4 Buys, 18 Holds and 5 Sells

Explore more price target data and ratings for Moderna, Inc. on the , and track all previous and future analyst recommendations for Moderna, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks](https://longbridge.com/en/news/290970667.md)
- [Moderna spotlights expanding mRNA pipeline at Science Day event](https://longbridge.com/en/news/290819631.md)
- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna publishes Science Day 2026 presentation](https://longbridge.com/en/news/290839905.md)
- [Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases](https://longbridge.com/en/news/290822266.md)